Cervical cancer is a common tumor in women and one of the common causes of cancer death in women. Due to the aggressive and non-specific nature of traditional chemotherapy, there is a growing need for new treatment modalities. Currently, tumor immunotherapy is increasingly garnering attention as a disruptive treatment approach. Therefore, we constructed CCTP-SmacN7, a delivery system capable of releasing active molecules in the tumor microenvironment. CCTP-SmacN7 can not only inhibit tumor proliferation and migration, but also induce tumors to produce large amounts of reactive oxygen species. The production of reactive oxygen species can activate tumors to release or expose damage-associated molecular patterns, promote DC cell maturation, and ultimately activate T cells. Here, we present an innovative targeted treatment approach for cervical cancer. While inducing tumor immunogenic cell death, this program can also improve the tumor microenvironment and initiate the tumor immune cycle.

宫颈癌是女性常见的肿瘤，也是女性癌症死亡的常见原因之一。由于传统化疗的侵袭性和非特异性，对新治疗方式的需求不断增长。目前，肿瘤免疫疗法作为一种颠覆性的治疗方法越来越受到关注。因此，我们构建了 CCTP-SmacN7，一种能够在肿瘤微环境中释放活性分子的递送系统。CCTP-SmacN7 不仅可以抑制肿瘤增殖和迁移，还可以诱导肿瘤产生大量的活性氧。活性氧的产生可以激活肿瘤以释放或暴露与损伤相关的分子模式，促进 DC 细胞成熟，并最终激活 T 细胞。在这里，我们提出了一种创新的宫颈癌靶向治疗方法。在诱导肿瘤免疫原性细胞死亡的同时，该程序还可以改善肿瘤微环境并启动肿瘤免疫周期。